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Abstract 25 
Background/Objectives: It is estimated that zinc deficiency affects 17% of the world's 26 
population and because of periods of rapid growth, children are at an increased risk of 27 
deficiency which may lead to stunting. This paper presents a systematic review and meta-28 
analysis of the randomised controlled trials that assess zinc intake and growth in children 29 
aged 1-8 years. This review is part of a larger systematic review by the European 30 
Micronutrient Recommendations Aligned (EURRECA) Network of Excellence that aims to 31 
harmonise the approach to setting micronutrient requirements for optimal health in European 32 
populations (www.eurreca.org).  33 
Subject/Methods: Searches were performed of literature published up to and including 34 
December 2013 using MEDLINE, Embase, and the Cochrane Library databases. Included 35 
studies were RCTs in apparently healthy child populations aged from 1 to 8 years that 36 
supplied zinc supplements either as capsules or part of a fortified meal. Pooled meta-analyses 37 
were performed when appropriate.  38 
Results: Nine studies met the inclusion criteria. We found no significant effect of zinc 39 
supplementation of between 2 weeks to 12 months duration on weight gain, HAZ, WAZ, 40 
LAZ, WHZ or WHZ scores in children aged 1-8 years. 41 
Conclusion: Many of the children in the included studies were already stunted and may have 42 
been suffering multiple micronutrient deficiencies and therefore zinc supplementation alone 43 
may have only a limited effect on growth.  44 
 45 
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INTRODUCTION 49 
Suboptimal dietary zinc intake is increasingly recognised as an important public health issue. 50 
It is estimated that the risk of low dietary intake of absorbable zinc and consequent zinc 51 
deficiency affects 17% of the world’s population.1 Factors that contribute to zinc deficiency 52 
include consumption of high phytate-containing cereal and low protein intake, commonly 53 
found in the diets of non-industrialised populations, which impairs zinc absorption.
2,3
 Zinc 54 
deficiency is particularly prevalent in South and Southeast Asia, Latin America and sub-55 
Saharan Africa.
2,4,5 
Frequent clinical infections such as diarrhoea, also common in non-56 
industrialised regions, also affect zinc absorption.
6,7
  57 
 58 
Children are particularly vulnerable to zinc deficiency due to an increased requirement during 59 
periods of rapid growth.
6
 Zinc deficiency may impair growth and contribute to stunting in 60 
children.
3,8,9
 One suggested mechanism is altered growth hormone metabolism.
10
 It has been 61 
estimated that 171 million children (167 million in developing countries) are stunted and 20% 62 
of children under 5 years in low and middle income countries have a WAZ score (weight for 63 
age Z score) of less than -2.
5
 While severe zinc deficiency is uncommon in European 64 
populations, marginal deficiency is likely to be much more prevalent.
11
 Although the global 65 
prevalence of childhood stunting has decreased in the last decade (from 39·7% in 1990 to 66 
26·7% in 2010), stunting remains a major public health problem.
12
  67 
 68 
Several systematic reviews have explored the relationship between preventive zinc 69 
supplementation and growth in children, but have reported discordant findings.
13-16
 A high 70 
degree of heterogeneity, however, was observed in many of the meta-analyses performed, 71 
due in part to inclusion of data from children with a wide age range in pooled analyses. 72 
Brown et al
13
 pooled data from infants and pre-pubertal children; Ramakrishnan et al
15
 and 73 
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Imdad et al
16
 pooled data from infants and children under 5 years of age and Brown et al
14
 74 
included infants, children and adolescents in their meta-analyses. Such wide-ranging ages 75 
incorporate several periods where growth is particularly rapid (during infancy and puberty for 76 
example) and during which the child's nutrient needs correspond with these changes in 77 
growth rates. Growth during the first year of life is particularly rapid, with more than a 78 
doubling of birth weight and a 50% increase in body length.
17
 The velocity of statural growth, 79 
which may reach as much as 30 cm/year in the first 2 months of life, decreases to a third of 80 
this rate by 10 months and continues to decline sharply until 2-3 years of age.
18
 After 2 years 81 
of age rates of weight gain and statural growth show a slow, downward trend and reach a 82 
nadir just before the beginning of the pubertal growth spurt, sometime between ages 9 and 83 
15.
19
 In order to minimise the confounding influence of combining disparate age groups we 84 
conducted a systematic review and meta-analysis of all available randomized controlled trials 85 
(RCTs), meeting the EURRECA inclusion criteria, which investigated the relationship 86 
between zinc intake and growth (height, weight gain, growth z scores) in children aged 1 -8 87 
years. 88 
 89 
METHODS 90 
Search strategy  91 
This research was conducted within the framework of the European Micronutrient 92 
Recommendations Aligned (EURRECA) Network of Excellence, that aims to harmonise the 93 
approach to setting the micronutrient requirements for optimal health in European 94 
populations (www.eurreca.org). This review was part of a wider review process to identify 95 
studies assessing the effect of zinc intake on different outcomes (biomarkers of zinc status 96 
and health outcomes). The wider searches were performed in literature published up to and 97 
including February 2010 using MEDLINE, Embase, and Cochrane, using search terms for 98 
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[‘study designs in humans’] AND [zinc] AND [intake OR status]. An updated search was 99 
conducted in December 2013. Both indexing and text terms were used. The full Ovid 100 
MEDLINE search strategy can be found as Supplementary information available at EJCN's 101 
website. Reference lists of retrieved articles and published literature reviews were also 102 
checked for relevant studies. Authors were contacted to request missing data or clarify 103 
methods or results. The search process is illustrated in Figure 1. 104 
 105 
Inclusion/exclusion criteria 106 
Included studies were RCTs in apparently healthy child populations aged from 1 to 8 years 
107 
that supplied supplemental zinc as an oral dose or as part of a fortified meal. If supplemental 
108 
zinc was provided as a component of a fortified meal, studies were only included if zinc was 
109 
the only constituent that was different between treatment groups. Only studies that reported 
110 
sufficient data or had sufficient data obtainable from the authors to estimate  ̂and SE( ̂) for 
111 
the assumed linear relation on the loge-loge scale were included. Studies were excluded if 
112 
they included infants aged <12 months or pubertal children aged ≥ 9 years, were conducted in 
113 
animals, or were group randomized controlled trials (community trials), case studies, 
114 
uncontrolled trials, commentaries, reviews, or duplicate publications from the same study. 
115 
Group randomised controlled trials were excluded from all reviews conducted by the 
116 
EURRECA consortium due to the increased risk of confounding factors, such as the outbreak 
117 
of disease, food shortage or differing school hours specific to each localized group, 
118 
influencing specific outcomes of interest. Studies were excluded if children were 
119 
hospitalised, had severe protein-energy malnutrition or a chronic disease or if supplemental 
120 
zinc was provided for less than 2 weeks. Only studies available in languages (English, Dutch, 
121 
French, German, Hungarian, Italian, Norwegian, Polish, Spanish, Greek and Serbian) spoken 
122 
by the EURRECA Network were included.  
123 
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 124 
Selection of articles 125 
Of 9653 identified articles in the wider 2010 and updated 2013 search on zinc intake, status 126 
and priority health outcomes in all populations, 5042 were excluded based upon screening of 127 
the title and abstract. Two independent reviewers screened 10% of the abstracts in duplicate 128 
and any discrepancies were discussed before screening the remaining references. Following 129 
subdivision into appropriate population groups the full texts of the 340 manuscripts were 130 
assessed to determine inclusion and exclusion by two independent reviewers and 131 
disagreements rectified through discussion. 292 studies were excluded because they did not 132 
meet the inclusion criteria. Of the remaining 48 studies, 29 studies were excluded because 133 
they had not investigated the relationship between zinc intake and childhood growth, but 134 
related either intake to status directly and were reported elsewhere
20
 or to a health endpoint 135 
other than growth. Six papers identified as reporting zinc intake and growth data were 136 
omitted from the review because there was lack of sufficient data on growth to calculate 137 
effect size, such as reporting growth velocity with no baseline data, or not providing the 138 
standard deviation or means to calculate the SD. A further 4 studies were omitted from the 139 
meta-analysis because they included children older than 8 years or younger than 12 months, 140 
despite the reported mean falling into the eligible age range. For the purpose of this review, 9 141 
RCTs met our inclusion criteria. As one paper,
21
 assessed three zinc doses in separate groups 142 
of participants, eleven estimates of zinc intake and child growth were eligible for meta-143 
analysis.  144 
 145 
Data extraction 146 
For each of the identified manuscripts, data were extracted into a standardized database. All 147 
data extracted from the papers were checked in duplicate. Extracted data included population 148 
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characteristics, dose of zinc in intervention and placebo supplements, duration of the study, 149 
dietary intake of zinc, weight, height for age (HAZ), weight for age (WAZ), length for age 150 
(LAZ), weight for height (WHZ) and weight for length (WLZ). 151 
 152 
Data synthesis  153 
If a change in weight or z-score was reported as well as the baseline data, the final value was 154 
calculated. If dietary intake of zinc (in addition to the intervention) was not reported we used 155 
a value of 5.65 mg/day, this was the mean dietary intake level of the RCTs (n=8) that did 156 
report dietary zinc intake. In instances where a factorial design was used only data where zinc 157 
was the only difference could be used. In the meta analyses, one study that included three 158 
zinc-treated groups and one control group was treated as three independent estimates.
21
 Four 159 
studies reported growth data at more than one time point and the growth data at the final time 160 
point was used for 2 of the studies,
22,23
 for the other two studies the growth data from the 6 161 
month and 3 month time point respectively was used as this was the closest measurement 162 
after the supplementation period ceased.
24,25
    163 
 164 
Statistical analyses 165 
Pooled meta-analyses were performed combining the evidence from the nine RCTs identified 166 
in the search. The transformations used to derive coherent single-study estimates from the 167 
available summary statistics per study have been described elsewhere.
26
 In short, we 168 
estimated an intake-growth regression coefficient ( ̂) for each individual study, based on the 169 
assumption of a linear relation on the loge-loge-scale (natural logarithm of intake versus 170 
natural logarithm of status). Algebraically deriving an estimate from each study of the 171 
regression coefficient ( ̂) and its standard error (SE( ̂)) enabled us to compare the results 172 
from studies with heterogeneously reported associations and effects. We calculated the 173 
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overall pooled  ̂  and SE(  ̂ ) using random effects meta-analysis, which estimates the 174 
between-study variance using the method of DerSimonian and Laird and used this estimate to 175 
modify the weights used to calculate the summary estimate. Residual heterogeneity between 176 
studies was evaluated using the I
2
 statistic. Meta analyses were run for six measures of 177 
growth; weight, HAZ, LAZ, WAZ, WHZ and WLZ. The statistical transformations to obtain 178 
 ̂’s and SE( ̂)’s were performed using GenStat version 13-SP2 (VSN International Ltd., 179 
http://www.vsni.co.uk/) and the meta-analysis was performed using STATA version 11.0 180 
(College Station, TX), with statistical significance defined as P<0.05.  181 
 182 
Assessment of risk of bias in included studies 183 
In order to assess the quality of the study and the risk of bias, indicators of internal validity 184 
were collected during data extraction. Based on the indicators, two independent reviewers 185 
assessed the overall risk of bias and each study was classified as low, moderate or high risk. 186 
The criteria for judging these indicators were adapted from the Cochrane Handbook.
27
  187 
 188 
RESULTS 189 
Eleven estimates of zinc intake and child growth in nine RCTs were eligible for meta-190 
analysis (Table 1). All studies were RCTs published between 1983 and 2008 which reported 191 
zinc intake and a growth outcome. The eleven estimates included a total of 1316 participants 192 
with sample sizes ranging from 20 to 165. One study was conducted in Africa, five in Central 193 
and South America, two in North America, and one in the Indian Sub-continent. All of the 194 
studies in this meta-analysis had low initial mean HAZ scores, below or approaching <-2.0 195 
with varying levels of stunting reported. Gibson et al
22
 included only male children and the 196 
remaining studies provided combined data on both boys and girls. Zinc was provided as zinc 197 
sulphate,
21-25,28,29
 zinc methionine
30
 or amino acid chelate as a chewable supplement,
31
 198 
9 
 
dissolved in a flavoured solution
30.
, fresh fruit juice
22,23
 or as a syrup
21,24,25,28,29.
 Only two 199 
studies reported that they attempted to administer the zinc under fasting condition
21,29
. The 200 
duration of the studies ranged from 2 to 12 months and the supplementation periods ranged 201 
from 14 days to 12 months. Supplement doses ranged from 3-20 mg Zn/d  (median 10 mg)  202 
and the doses were provided daily in most studies.
21,22,24,25,28,29
 Some studies, however, 203 
provided zinc supplements several times per week
23,30,31
 resulting in daily dose equivalents 204 
ranging from 7.14 to 14.29 mg zinc/day. 205 
 206 
Weight 207 
Weight was assessed in three studies.
21,23,31
 Whilst weight gain was observed to occur in all 208 
included studies in both zinc supplemented and placebo groups, no significant differences 209 
between the zinc supplemented and placebo groups at the end of the study were reported 210 
(Table 1). Consequently no significant pooled effect of zinc supplementation was found for 211 
weight change (pooled beta-coefficient of 0.01; 95% CI -0.01, 0.02; Fig 2). The studies in 212 
this meta-analysis were homogenous (I-squared 0.0%, p=0.852).  213 
 214 
HAZ Score 215 
None of the 7 studies that reported HAZ scores
22-24,28-31
 found a significant difference 216 
between the zinc supplemented and placebo groups at the end of the study and a pooled 217 
analysis found no significant association between zinc supplementation and change in HAZ 218 
score (pooled beta-coefficient 0.04; 95% CI -0.13, 0.22; Fig 3). The studies in this meta-219 
analysis were homogenous (I-squared 48.6%, p=0.070).  220 
 221 
WAZ Score 222 
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Eight studies reported WAZ scores.
21-25,28,30,31
 None of these studies reported a significant 223 
difference in WAZ score between the zinc supplemented and placebo groups at the end of the 224 
study. Rahman et al
25
 reported WAZ score gains in both the zinc supplemented and placebo 225 
group but the difference between the two groups was not significantly different. Our pooled 226 
analysis revealed no statistically significant association between zinc supplementation and 227 
change in WAZ score in children aged between 1-8 years (pooled beta-coefficient 0.04; 95% 228 
CI: -0.04, 0.12; Fig 4). The studies in this meta-analysis were highly homogenous (I-squared 229 
0.0%, p=0.586).  230 
 231 
LAZ Score 232 
Only two studies investigated the relationship between LAZ and zinc supplementation and 233 
neither found a significant difference between zinc supplemented and placebo groups at the 234 
end of the study, although both reported an increased LAZ in both zinc supplemented and 235 
placebo groups over the duration of the studies.
21,25
 Our pooled analysis confirmed that zinc 236 
supplementation was not significantly associated with a change in LAZ score in children 237 
aged between 1-8 years (pooled beta-coefficient -0.001; 95% CI -0.11, 0.10; Fig not shown). 238 
The studies in this meta-analysis were homogenous (I-squared 0.0%, p=0.780).  239 
 240 
WLZ Score 241 
Two studies investigated the relationship between WLZ and zinc supplementation and neither 242 
found a significant difference in WLZ score between the zinc supplemented and placebo 243 
groups at the end of the study.
21,25
 Wuehler et al
21
 reported an improved WLZ score over 244 
time in both zinc supplemented and placebo groups, whilst Rahman et al
25
 reported a decline 245 
in WLZ scores over time in both zinc supplemented and placebo groups. A pooled analysis 246 
confirmed that zinc supplementation was not significantly associated with a change in WLZ 247 
11 
 
score (pooled beta-coefficient 0.05; 95% CI: -0.04, 0.14; Fig not shown). The studies in this 248 
meta-analysis were homogenous (I-squared 0.0%, p=0.612).  249 
 250 
WHZ Score 251 
Four studies investigated WHZ score in children
22,28-30
 but none found a significant difference 252 
in WHZ score between the zinc supplemented and placebo groups at the end of the study. A 253 
pooled analysis confirmed that zinc supplementation was not significantly associated with a 254 
change in WHZ score in this population (pooled beta-coefficient 0.02; 95% CI -0.11, 0.16; 255 
Fig 5). The studies in this meta-analysis were homogenous (I-squared 0.0%, p=0.705).  256 
 257 
Risk of bias 258 
The risk of bias was low for Rahman et al
25
 and Wuehler et al
21
 moderate for Walravens et 259 
al
28
, Sempertegui et al
24
 and Kikafunda et al
23
 and high for the remaining four studies 260 
(Supplementary information is available at EJCN's website).
22,29-31
 Papers were given a high 261 
risk of bias rating due to reasons such as insufficient information provided on sequence 262 
generation and/or allocation, study blinding, drop-outs and funding bodies. 263 
 264 
DISCUSSION 265 
This systematic review was undertaken to investigate the association between zinc intake and 266 
indices of growth in children aged between 1 and 8 years of age. Eleven estimates in nine 267 
RCTs, which enrolled a total of 1316 children, were included in seven meta-analyses. In 268 
pooled analyses, no statistically significant effects of zinc supplementation were found on 269 
weight, HAZ, WAZ, LAZ, WHZ and WLZ scores in children of this age group. A major 270 
strength of the current review is the meta-analysis of statistically homogenous studies. 271 
12 
 
Although previous meta-analyses found statistically significant effect sizes on various aspects 272 
of child growth, all have suffered from high heterogeneity. 273 
 274 
Four systematic reviews have been published that have investigated the relationship between 275 
zinc supplementation and growth in children, but there is considerable variability in their 276 
review inclusion criteria making it difficult to provide firm conclusions about the nature of 277 
this relationship.
13-16
 In contrast to our study, the two systematic reviews by Brown et al
13,14
 278 
reported statistically significant positive effects of zinc supplementation on linear growth and 279 
weight gain. A marginally statistically significant effect of zinc on change in WHZ was 280 
reported by Brown et al
14
, but not in their earlier study.
13
 Imdad et al
16
 also reported a 281 
significant positive effect of zinc supplementation on linear growth. Statistically significant 282 
heterogeneity was found among the studies included in linear growth and weight gain meta-283 
analyses in all three reviews, likely to be due in part to the inclusion of data from infants, 284 
children and/or adolescents. In addition, Brown et al included hospitalised, severely 285 
malnourished children in their 2002 meta-analyses
13
, although excluded such children in their 286 
subsequent review.
14
  287 
 288 
Our findings confirm those of Ramakrishnan et al
15
 who found no significant effect of zinc 289 
supplementation on height or weight gain in 43 studies of children under 5 years of age. They 290 
did, however, report a small positive effect (effect size = 0.06; 95% CI: 0.006, 0.11) on 291 
change in WHZ. This review differs from ours in that more than half of their included studies 292 
were conducted in infants (initial age <12 months) and some studies included small-for-293 
gestational age infants.  294 
 295 
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Our review has combined homogenous studies to provide an accurate estimate of the 296 
influence of zinc supplementation on measures of growth in children. We achieved high 297 
homogeneity in our meta-analyses by restricting the age group. We also excluded studies that 298 
have been included in previous reviews that involved anaemic or malnourished children, 299 
children who were low birth weight or small for gestational age and community trials. 300 
 301 
Whilst all studies included in our meta-analyses were undertaken in individuals without 302 
chronic disease or severe protein-energy malnutrition, other factors such as infection and 303 
inflammation may also have gone unreported. For example, only one study screened and 304 
excluded participants with parasitic infection,
29
 other studies treated pre-existing 305 
micronutrient deficiencies by supplementing the children with multivitamin and/or mineral 306 
supplements during the baseline
31
 or pre-baseline
21
 period. Other limitations include the 307 
absence of large well designed trials, lack of studies that attempt to administer zinc under 308 
fasting conditions to avoid the influence of dietary factors such as phytate on zinc 309 
bioavailability, and the lack of data provided on baseline nutritional status which make it 310 
difficult to identify the conditions under which these interventions may be beneficial. The 311 
non significant effect of supplemental zinc on childhood growth identified in this meta 312 
analysis, however, cannot be explained by an ineffective absorption of zinc from a 313 
supplement per se because the fractional absorption of zinc from supplements is comparable 314 
to that of a phytate free meal
32,33
.  315 
 316 
 317 
CONCLUSIONS 318 
The methods employed to conduct this review were thorough and robust allowing only the 319 
most rigorous and well-designed studies to be included, while reducing the impact that 320 
14 
 
confounding factors may have. The resulting meta analyses suggested no statistically 321 
significant improvement of several indices of childhood growth following zinc 322 
supplementation in children aged 1-8 years of age. As most of the studies included in the 323 
review involved children who were stunted, it is likely that multiple micronutrient 324 
deficiencies exist which is why zinc alone did not significantly improve growth. 325 
 326 
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Figure Legends 448 
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Figure 1. Study selection process 450 
 451 
Figure 2. Random effects meta-analyses of RCTs evaluating the effect of dietary zinc on 452 
weight gain in children aged 1-8 years old. Beta’s represent the regression coefficients for the 453 
linear association between log transformed zinc intake and weight growth. 454 
 455 
Figure 3. Random effects meta-analyses of RCTs evaluating the effect of dietary zinc on 456 
HAZ score in children aged 1-8 years old. Beta’s represent the regression coefficients for the 457 
linear association between log transformed zinc intake and HAZ score 458 
 459 
Figure 4. Random effects meta-analyses of RCTs evaluating the effect of dietary zinc on 460 
WAZ score in children aged 1-8 years old. Beta’s represent the regression coefficients for the 461 
linear association between log transformed zinc intake and WAZ score. 462 
 463 
Figure 5. Random effects meta-analyses of RCTs evaluating the effect of dietary zinc on 464 
WHZ score in children aged 1-8 years old. Beta’s represent the regression coefficients for the 465 
linear association between log transformed zinc intake and WHZ score. 466 
 467 
Figure 1. Study selection process for systematic review.  
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Figure 2. Random effects meta-analyses of RCTs evaluating the effect of dietary zinc on 
weight gain the children ages 1-8 years old. Beta’s represent the regression coefficients for 
the linear association between loge transformed zinc intake and weight growth. 
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Figure 3. Random effects meta-analyses of RCTs evaluating the effect of dietary zinc on 
HAZ score in children ages 1-8 years old. Beta’s represent the regression coefficients for the 
linear association between loge transformed zinc intake and HAZ score. 
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Figure 4. Random effects meta-analyses of RCTs evaluating the effect of dietary zinc on 
WAZ score in children ages 1-8 years old. Beta’s represent the regression coefficients for the 
linear association between loge transformed zinc intake and WAZ score. 
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Figure 5. Random effects meta-analyses of RCTs evaluating the effect of dietary zinc on 
WHZ score in children ages 1-8 years old. Beta’s represent the regression coefficients for the 
linear association between loge transformed zinc intake and WHZ score. 
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  Table 1: Summary of included trials reporting the effect of dietary zinc intake on growth outcomes in children. 
 
Study, year, 
country 
 
Sex, Age, Stunting Treatment groups 
 
Micronutrient 
type 
 
Study Duration 
 
Measurement 
Time point 
 
Supplementation 
Duration 
Growth outcome Mean (SD) 
 
Significant results 
Cavan et al (1993), 
Guatemala 
 
Males and females 
aged 81.5 ±7.0 
months2.  
 
Initial mean HAZ -1.4.  
Placebo (n80) 
10 mg Zn/d school days only (n76) 
 
(all participants also received MN 
supplements) 
Amino Acid 
Chelate  
25 weeks 
 
25 weeks 
 
25 weeks 
HAZ 
 
Height (cm) 
 
WAZ 
 
Weight (kg) 
 
WHZ 
(P) -1.281±0.98 
(Z) -1.521±0.73 
(P) 115.71±4.96 
(Z) 115.21±4.74 
(P) -0.761±0.85 
(Z) -0.791±0.75 
(P) 211±2.59 
(Z) 211±2.89 
(P) 0.231±0.70 
(Z) -0.311±0.89 
None 
Gibson et al (1989),  
Canada 
 
Males aged 59-95 
months.  
 
Initial mean HAZ -1.4.   
Placebo (n30) 
10 mg Zn/d (n30) 
 
Zinc Sulphate   12 months 
 
12 months 
 
12 months 
HAZ 
 
WAZ 
 
WHZ 
 
(P) -1.26±0.44 
(Z) -1.23±0.44 
(P) -1.26±0.44 
(Z) -1.23±0.44 
(P) -1.07±0.66 
(Z) -0.90±0.57 
None 
Kikafunda et al 
(1998),  
Uganda 
 
Males and females 
aged 33-89 months.  
 
Initial mean HAZ -0.7  
Placebo (n54) 
10 mg Zn/d 5 days per week (n59) 
Zinc Sulphate 8 months 
 
8 months 
 
2 x 3 months 
supplemented 
phases, separated 
by a 2 month non 
supplemented 
phase.  
HAZ 
 
Height (cm) 
 
WAZ 
 
Weight (kg) 
(P) -0.48±0.95 
(Z) -0.50±0.92 
(P) 107.95±5.4 
(Z) 108.10±5.5 
(P) -0.27±0.7 
(Z) -0.27±0.88 
(P) 17.95±2.1 
(Z) 18.06±2.1 
None 
Rahman et al 
(2002), Bangladesh 
 
Males and females 
aged 12-35 months. 
 
Initial mean LAZ -2.4 
Placebo (n160) 
20mg Zn/d for 14 days (n165) 
Zinc Sulphate 6 months 
 
3 months 
 
14 days 
WAZ 
 
LAZ 
 
WLZ 
(P) -2.19±0.89 
(Z) -2.25±0.89 
(P) -2.31±1.18 
(Z) -2.42±1.16 
(P) -1.08±0.76 
(Z) -1.04±0.74 
None 
Rosado et al (1997), 
Mexico 
 
Males and females 
aged 18-36 months.  
 
Placebo (n47) 
20 mg Zn/d 5 days per week (n48) 
Zinc Methionine 12 months 
 
12 months 
HAZ 
 
WAZ 
(P) -1.67±0.89 
(Z) -1.44±1.03 
(P) -1.15±0.59 
None 
Initial mean HAZ -1.7   
12 months 
 
WHZ 
 
(Z) -1.14±0.88 
(P) -0.11±0.59 
(Z) -0.15±0.59 
Sempertegui et al 
(1996),  
Ecuador 
 
Males and females 
aged 12-59 months. 
 
Initial mean HAZ -2.0 
Placebo (n25) 
10mg Zn/d (n23) 
Zinc Sulphate 120 days 
 
60 days 
 
60 days 
HAZ 
 
WAZ 
 
(P) -1.7±0.8 
(Z) -1.8±0.7 
(P) -1.30±0.5 
(Z) -1.30±0.6 
None 
Silva et al (2006), 
Brazil 
 
Males and females 
aged 12-59 months.  
 
Initial mean HAZ -2.0 
Placebo (n30) 
10 mg/d Zn/d (n28) 
 
(all participants also received Fe 
fortified milk) 
Zinc Sulphate 4 months 
 
4 months 
 
4 months 
HAZ 
 
WHZ 
(P) -1.6±1.6 
(Z) -1.7±2.6 
(P) 0.6±1.6 
(Z) 0.7±1.5 
None 
Walravens et al 
(1983),  
USA 
 
Males and females 
aged 24-72 months. 
 
Initial mean HAZ -2.0  
Placebo (n20) 
5 mg Zn/d (n20) 
Zinc Sulphate 12 months 
 
12 months 
 
12 months 
HAZ 
 
WAZ 
 
WHZ 
 
(P) -2.22±0.6* 
(Z) -1.80±0.34* 
(P) -1.71±0.55 
(Z) -1.41±0.48 
(P) -0.45±0.58 
(Z) -0.36±0.68 
HAZ was sig (p<0.05) 
higher in the zn 
supplemented group with 
the male but not female 
subgroup analysis. 
Wuehler et al 
(2008),  
Ecuador 
 
Males and females 
aged 12-36 months. 
 
Initial mean LAZ -2.3 
Placebo (n108) 
(S1) 3 mg Zn/d (n103) 
(S2) 7 mg Zn/d (n100) 
(S3) 10 mg Zn/d (n110) 
Zinc Sulphate 
 
6 months 
 
6 months 
 
6 months 
WAZ 
 
 
 
Weight (kg) 
 
 
 
LAZ 
 
 
 
WLZ 
(P) -1.26±0.8 
(S1Z) -1.13±0.8 
(S2Z) -1.14±0.7 
(S3Z) -1.18±0.8 
(P) 10.7±1.3 
(S1Z) 10.9±1.3 
(S2Z) 10.8±1.2 
(S3Z) 10.7±1.4 
(P) 10.7±1.3 
(S1Z) 10.9±1.3 
(S2Z) 10.8±1.2 
(S3Z) 10.7±1.4 
(P) -0.16±0.8 
(S1Z) -0.01±0.9 
(S2Z) -0.05±0.8 
(S3Z) -0.13±1.0 
None 
  
1
 = Median 
2
 = No age range reported 
*
 = Significant result P=<0.05 
MN = micronutrients 
P = Placebo group 
Z = Zinc group 
S1 = Study 1 
S2 = Study 2  
S3 = Study 3 
 
